In cancer cells, multiple mechanisms are able to disrupt the inactive conformation of SFKs including binding of SH2 to activated receptors such as flt3 (in AML) and to oncogenic protein kinase such as BCR-ABL (in CML and ALL) [152]. Here, ABL1 is linked to cancer.